PLSE

Pulse Biosciences, Inc. Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Pulse Biosciences, Inc. (PLSE) on January 31, 2025, with the report date of February 4, 2025. The filing discloses the appointment of a new Chief Financial Officer and details the associated compensatory arrangements.

Key Financial Metrics

The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and employment terms.

Material Changes

The primary material change reported is the appointment of Jon Skinner as Chief Financial Officer and Principal Financial Officer, effective February 3, 2025. Mr. Skinner replaces the previous leadership in this role, bringing experience from Copeland, Imperative Care, and Teleflex.

Compensation, Outlook, and Risks

Compensation Package:

• Base Salary: $400,000 annually.
• Target Bonus: 50% of base salary ($200,000), subject to performance objectives.
• Sign-on Bonus: Up to $56,000.
• Equity Grant: 300,000 stock options at an exercise price of $20.93 per share (closing price on Jan 31, 2025).

Equity Vesting Schedule:

• Time-Based Vesting: 50% of options (150,000 shares) vest over four years (12.5% annually starting the first anniversary).
• Performance-Based Vesting: 50% of options (150,000 shares) vest upon achieving specific market capitalization and GAAP product revenue milestones over 270 consecutive days:

1. Milestone 1: $2.0B Market Cap and $8M Revenue (37,500 shares).
2. Milestone 2: $3.0B Market Cap and $48M Revenue (37,500 shares).
3. Milestone 3: $4.0B Market Cap and $115M Revenue (37,500 shares).
4. Milestone 4: $5.0B Market Cap and $175M Revenue (37,500 shares).

Outlook and Risks:
The performance milestones imply management's strategic targets for significant growth in market valuation and product revenue. The filing notes no reportable family relationships or related party transactions involving Mr. Skinner.

Investor Verification Checklist

• Verify the exact vesting conditions and acceleration clauses in the full Employment Agreement (Exhibit 10.1).
• Confirm the current market capitalization and trailing twelve-month GAAP product revenue to assess proximity to the first performance milestone.
• Review the press release (Exhibit 99.1) for additional context on the strategic rationale for the appointment.
• Monitor future filings for any changes to the compensation structure or achievement of the stated performance milestones.